# 2QFY26 Earnings Webinar

Sunshine Holdings PLC

10 November 2025

# Housekeeping Announcements

- The webinar will be recorded and later uploaded to our IR website as well as CSE website for future reference (https://www.sunshineholdings.lk/investor-relations/)
- All participants will be muted during the presentation
- Participants can use the 'Raise Hand' option to ask questions during the Q&A session, and we will unmute them accordingly
- Participants can also raise their questions via the chat box

# Team

## Sunshine Holdings



**Shyam Sathasivam**
*Group CEO*



**Aruna Deepthikumara**
*Group CFO*

## Sunshine Healthcare



**Shantha Bandara**
*CEO - Sunshine Pharmaceuticals and Healthguard Distribution*



**Dr. Thiru Sayandhan**
*CEO - Sunshine Medical Devices and Lina Manufacturing*



**Farman Nizar**
*COO - Healthguard Pharmacy*

## Sunshine Consumer



**Anuruddha Aluvihare**
*CEO – Sunshine Consumer*



**Sanjeeva Saranapala**
*CEO – Sunshine Tea*

# Corporate Announcements

- Sunshine Holdings PLC has declared a first interim dividend of Rs. 0.60 per share for FY26 (XD date - 17 Nov 2025, Payment date - 05 Dec 2025)
- Watawala Plantations PLC declared a first interim dividend of Rs. 1.70 per share for FY26 (XD date: 14 Nov 2025; payment date: 03 Dec 2025)

# Group Performance

# Group at a glance – 2QFY26

## Revenue Composition – 2QFY26




| | | |
|---|---|---|
| LKR 2.8bn | LKR 1.3bn | LKR 0.35 |
| 11.3% YoY | -14.7% YoY | -43.7% YoY |
| **EBIT** | **Earnings** | **EPS** |

| | | |
|---|---|---|
| 22.8% | 23.5% | LKR 10.53 |
| -5.0 pts YoY | +0.1 pts YoY | 4.7% YoY |
| **Gearing** | **ROE** | **NBV** |

| | | |
|---|---|---|
| LKR 64.0bn | 18.8x | 4.5% - FY25 |
| +110.0% YoY | +168.4% YoY | 5.0% - FY24 |
| **Mkt Cap** | **PER** | **Div Yield** |

Footnote : 1- Share price details as of 30th September 2025, **LKR 32.50**

# Key ratios – 1HFY26

## INVESTOR RATIOS

| | 1HFY26 | 1HFY25 |
|---|---|---|
| | LKR 1.92 | LKR 2.07 |
| | EPS TTM | EPS TTM |
| | 23.49% | 23.41% |
| | ROE | ROE |
| | 16.95 | 7.47 |
| | PER TTM | PER TTM |
| | 10.53 | 10.06 |
| | NAV | NAV |
| | 3.09 | 1.54 |
| | PBV | PBV |

## PROFITABILITY RATIOS

| | 1HFY26 | 1HFY25 |
|---|---|---|
| | 31.9% | 30.4% |
| | GP Margin | GP Margin |
| | 17.0% | 15.4% |
| | EBIT Margin | EBIT Margin |
| | 9.2% | 9.7% |
| | PAT Margin | PAT Margin |

Footnote : 1- Share price details as of 30th September 2025, **LKR 32.50**

# Group – Performance Highlights

| LKR m | 2QFY26 | 2QFY25 | YoY % | 1QFY26 | QoQ % |
|---|---|---|---|---|---|
| Revenue | 16,396 | 15,812 | 3.7% | 15,893 | 3.2% |
| EBIT | 2,846 | 2,557 | 11.3% | 2,645 | 7.6% |
| *EBIT margin* | *17.4%* | *16.2%* | | *16.6%* | |
| PAT | 1,320 | 1,548 | -14.7% | 1,660 | -20.5% |
| *PAT margin* | *8.0%* | *9.8%* | | *10.4%* | |
| EPS (LKR) | 0.35 | 0.63 | -43.7% | 0.51 | -31.0% |

- Driven by margin expansion in the both Agribusiness and Consumer segments, GP improved by 5.1% YoY to LKR 5.3 bn in 2QFY26, with the gross margin improving to 32.1% cf. 31.7% in 2QFY25.
- Earnings before interest and taxes (EBIT) rose 11.3% YoY to LKR 2.8 bn, with the EBIT margin improving by 118 bps to 17.4%, following margin improvements in the Agri and Consumer segments, which helped offset the contraction in Healthcare.
- PAT margins declined by 174 bps to 8.0%, primarily due to lower Healthcare sector contribution, impacted by lower Manufacturing performance and an internal business model realignment.
- This business model realignment resulted in a one-off incremental tax provisions of LKR 310mn

*FY25 EPS adjusted for the share split

# Movement in Revenue & EBIT

## Revenue Movement [LKR Million]




## EBIT Movement [LKR Million]




## Revenue Composition – Revenue QoQ



# Healthcare

# Sunshine Healthcare Lanka (SHL) is Sri Lanka's only fully integrated healthcare company encompassing the entire pharma value chain

sunshine healthcare

sunshine healthcare

**2QFY26**

**8.7 bn**
**Revenue**

**12.2 %**
**EBIT Margin**

**2.4 %**
**PAT Margin**

## Manufacturing and R&D

Sri Lanka's first facility for Respiratory Care Research and Manufacturing, producing Respiratory Care Products and an Inhaler Device

**Government and Local market**

Capsules | Tablets | Nasal Spray | Devices | Creams | MDI

**Contract manufacturing**

KALBE

## Importation and Agency

Sri Lanka's third largest (10.29% market share) importer in the Pharma and Medical Devices segment with access to 75+ principals

**Key principals**

CADILA PHARMACEUTICALS LIMITED | Zydus Cadila | novo nordisk | Glenmark | Abbott | SIEMENS | Erba Mannheim | 3M | Johnson & Johnson | GE Healthcare

## Retail (Pharmacy)

Healthguard Pharmacy, has grown to 16 outlets in the Colombo district, becoming Sri Lanka's leading Health and Wellness chain

- Complete pharma offering
- Skilled, Educated, Qualified, Pharmacists
- Range & depth in wellness
- Digital centric organizational model

## Distribution

Fully-fledged distribution division to assist local pharmaceutical importers and manufacturers in expanding their reach among retail pharmacy outlets across Sri Lanka

- Six distribution centers with 25,000 sqft storage and 24x7 cold chain management
- Reaches 3,500 outlets in 620 towns, with scalable operations and fleet.

**Revenue Split 2QFY26**




**Total Asset Split 2QFY26**




Footnote : 1- Included under Importation and Agency

# Healthcare Sector – Highlights

## Sector Highlights

Healthcare sector revenue grew 1.7% YoY in 2QFY26, driven by sustained momentum across the agency, distribution, and retail businesses

However, the sector's overall profitability was impacted by a slowdown in the manufacturing business and one-off incremental tax provisions from internal model realignment.




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | 13.9% | 13.3% | 20.2% | 0.9% | 15.9% | -9.8% | 14.0% | 10.5% | 1.7% | 1.1% |
| EBIT Margin (%) | 18.5% | | 19.8% | | 13.8% | | 14.0% | | 12.2% | |
| PAT | 1,059 | | 1,134 | | 673 | | 765 | | 210 | |
| PAT Margin (%) | 12.4% | | 13.1% | | 8.6% | | 8.9% | | 2.4% | |
| ROIC (%) | 24.7% | | 27.4% | | 31.1% | | 31.0% | | 20.2% | |

LKR Million unless stated otherwise

# Sunshine Pharmaceuticals – Performance Highlights

## Business Highlights

The pharmaceutical segment's revenue grew by 64.8% YoY in 2QFY26, driven by the internal realignment of the business model.

Adjusting for this one-off impact, the RD segment grew 9.1% YoY during the 1HFY26 (Volume growth of 9.4% YoY), underscoring the continued organic growth across core agency portfolios

During IQVIA 2Q, the market experienced a growth of 7.3% (IQVIA - 2025 MAT%)




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | 17.5% | 32.8% | 10.5% | -25.1% | 14.3% | 14.3% | 26.7% | 11.5% | 64.8% | 72.8% |
| Volume Growth (%) | 8.1% | | 17.5% | | 12.0% | | 16.9% | | 7.6% | |
| Market Share (%) | 13.0% | | 13.0% | | 12.8% | | 10.4% | | 10.3% | |

LKR Million unless stated otherwise

**Market Dynamics Hyperlink**



# Healthguard Distribution – Performance Highlights

## Business Highlights

The Distribution segment's revenue grew by 17.4% YoY in 2QFY26, driven by a significant volume increase of 21.4% YoY during the quarter

This volume growth was mainly due to the business model realignment as well as contributions from new partnerships during the quarter




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | 17.2% | 23.6% | 32.3% | 2.2% | 28.0% | 0.9% | 44.5% | 13.4% | 17.4% | 0.4% |

LKR Million unless stated otherwise,

* Approximately 79% of the revenue is generated from internal customers in 2QFY26, which are classified as intercompany sales

# Sunshine Medical Devices – Performance Highlights

## Business Highlights

The Medical Devices segment recorded a 6.9% YoY revenue growth in 2QFY26, reflecting improved performance during the quarter




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | -31.2% | 8.4% | -1.1% | 24.2% | 10.1% | -19.9% | 17.2% | 8.7% | 6.9% | -1.1% |

LKR Million unless stated otherwise

Market Dynamics Hyperlink



# Lina Manufacturing – Performance Highlights

## Business Highlights

During 2QFY26, revenue from the manufacturing business declined by 15.0% YoY, primarily due to the reduction in government purchase orders for the 2025 calendar year




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | 118.0% | -2.9% | 88.8% | 33.2% | -28.1% | -70.1% | -19.6% | 107.6% | -15.0% | 2.7% |
| MDI Capacity Utilization (%)* | 75% | | 51% | | 19% | | 74% | | 91% | |

LKR Million unless stated otherwise

*MDI Capacity Utilization calculation was updated to reflect the 24x7 manufacturing

# Healthguard Pharmacy – Performance Highlights

## Business Highlights

The retail segment, Healthguard Pharmacy, recorded a 12.9% YoY increase in revenue for 2QFY26, driven by volume and value growth across both pharmaceutical and wellness ranges




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | 9.5% | 6.3% | 3.7% | 4.2% | 13.7% | 2.8% | 17.4% | 3.1% | 12.9% | 2.2% |
| Same store sales (SSS) growth (%)* | 4.5% | | 1.5% | | 12.0% | | 13.8% | | 9.0% | |
| Bill count growth (SS) (%) | 1.0% | | -0.9% | | 5.6% | | 17.9% | | 6.6% | |
| Average Basket Value growth (SS) (%) | 4.1% | | 2.5% | | 6.0% | | -0.4% | | 2.2% | |
| Availability (Top Pharma SKUs) (%) | 85% | | 83% | | 83% | | 83% | | 88% | |

LKR Million unless stated otherwise

* Starting 1QFY26, same store outlet classification will increase to 15, whereas previous comparative figures will account only for 13 stores

# Consumer Brands

# Sunshine Consumer, Market leader in branded tea and confectionery

sunshine consumer

2QFY26

**5.0 bn**
**Revenue**

**9.6 %**
**EBIT Margin**

**5.6 %**
**PAT Margin**

## Tea

Largest branded tea company in Sri Lanka – 49.2% market share*

*Peppercube Retail Measurement Survey Value Share

Catering to three distinct need and value segments, the portfolio comprising of three brands: Zesta, Watawala and Ran Kahata

## Confectionery

Market leader in the hard-boiled candies category: 40.7% market share

Brands consist of Daintee, Milady, X-tra and Daintee Hearts

## Exports

Exports value-added-tea products, including procuring, blending, packaging, and contract manufacturing of tea for private labels

Exports to 40+ countries, including USA, China, Iran, Dubai and Germany

### Brand Portfolio

Zesta, Ran, Watawala, Daintee, Milady, X-tra, Gordon Frazer, Tetley, Ahmad Tea London

### Revenue Split 2QFY26




### Total Asset Split 2QFY26



# Consumer Sector – Highlights

## Sector Highlights

The Consumer sector, including both export and domestic businesses, recorded a slight revenue decline of 1.5% YoY in 2QFY26, primarily due to weaker performance in the export segment.

Segment profitability, however, continued to improve, supported by improved operational efficiencies and tighter cost management.




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | 1.1% | 9.7% | -8.3% | -6.9% | -2.7% | -7.1% | 3.7% | 9.3% | -1.5% | 4.2% |
| EBIT Margin (%) | 6.5% | | 8.0% | | 6.3% | | 5.8% | | 9.6% | |
| PAT | 154 | | 196 | | 142 | | 157 | | 278 | |
| PAT Margin (%) | 3.0% | | 4.2% | | 3.3% | | 3.3% | | 5.6% | |
| ROIC (%) | 13.2% | | 10.0% | | 12.1% | | 12.6% | | 13.7% | |

LKR Million unless stated otherwise

# Tea – Performance Highlights

## Business Highlights

Revenue from the Branded Tea business grew by 8.3% YoY to **LKR 2.6 Bn** in 2QFY26, driven by the continued success of region specific strategies and brand-building initiatives.

Our core tea brands, Zesta, Watawala Thei and Ran Kahata, continued to perform well, each demonstrating resilience across the premium, mass market, and value-for-money segments.




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | -8.3% | 8.4% | -19.3% | 1.0% | 7.6% | -0.8% | 1.5% | -6.5% | 8.3% | 15.6% |
| Volume (kgs '000) | 1,225 | | 1,247 | | 1,231 | | 1,161 | | 1,352 | |
| Volume Growth % (YoY) \| (QoQ) | 5.9% | 6.5% | -8.4% | 1.8% | 2.5% | -1.3% | 1.0% | -5.7% | 10.4% | 16.5% |
| Market Share (%) – Quarter Average | 47.5% | | 48.7% | | 48.2% | | 47.6% | | 48.9% | |

LKR Million unless stated otherwise

Market Dynamics Hyperlink



# Confectionery – Performance Highlights

## Business Highlights

Revenue from the Confectionery business declined by 5.5% YoY in 2QFY26 due to heightened competition. However, the segment maintained steady momentum quarter-over-quarter, recording a 5.3% increase.




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | -14.9% | 33.5% | -46.0% | -31.5% | -8.1% | 22.4% | 19.9% | 7.0% | -5.5% | 5.3% |
| Volume (kgs '000) | 524 | | 351 | | 449 | | 463 | | 492 | |
| Volume Growth % (YoY) \| (QoQ) | -13.1% | 36.5% | -46.6% | -33.0% | -11.4% | 27.9% | 20.6% | 3.1% | -6.1% | 6.3% |
| Market Share (%) – Quarter Average | 20.1% | | 18.8% | | 17.2% | | 14.8% | | 14.6% | |

LKR Million unless stated otherwise

Market Dynamics Hyperlink



# Exports – Performance Highlights

## Business Highlights

Despite an increase in export volumes, the business recorded a revenue contraction of 9.2% YoY in 2QFY26 to reach **LKR 1.9 Bn.**

This was mainly due to a reduction in high-value tea product categories following the adverse impact of U.S. tariff adjustments.




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | 22.9% | 5.8% | 37.4% | -9.2% | -9.5% | -17.2% | 7.2% | 34.9% | -9.2% | -10.5% |
| Volume (kgs '000) | 841 | | 865 | | 654 | | 1,067 | | 948 | |
| Volume Growth % (YoY) \| (QoQ) | 6.3% | -7.0% | 44.5% | 2.9% | -18.4% | -24.4% | 18.0% | 63.1% | 12.7% | -11.2% |

LKR Million unless stated otherwise

# Agribusiness

# Watawala Plantations PLC primarily engages in palm oil and dairy farming

Watawala Plantations PLC

2QFY26

**2.7 bn**
**Revenue**

**49.3 %**
**EBIT Margin**

**33.3 %**
**PAT Margin**

## Palm Oil

A land extent of ~3,400 Ha under palm oil cultivation

The first in South Asia to receive RSPO certification for sustainable oil palm plantation

Positioning – largest oil palm cultivator in Sri Lanka

## Dairy

737 milking cows / 1,592 herd

Board of Investment (BOI) registered project which commercial operations in Aug 2017

DAIRYMASTER milking parlour system capable of monitoring the progress of each animal's yield and quality of milk produced

### Revenue Split 2QFY26




### Total Asset Split 2QFY26



# Agribusiness – Highlights

## Sector Highlights

The Agribusiness sector reported revenue of **LKR 2.7 Bn** in 2QFY26, reflecting a 23.0% YoY improvement, driven by the performance of the palm oil business.

GP margin for 2QFY26 improved to 57.6% from 42.1% same period last year.




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | -2.2% | 6.2% | -6.3% | -19.4% | 4.4% | 8.6% | 20.6% | 29.8% | 23.0% | 8.3% |
| EBIT Margin (%) | 33.4% | | 42.5% | | 30.6% | | 48.8% | | 49.3% | |
| PAT / PAT Margin (%) | 402 | 18.4% | 488 | 27.6% | 412 | 21.5% | 826 | 33.2% | 899 | 33.3% |
| ROIC (%) | 28.1% | | 29.1% | | 33.7% | | 45.5% | | 41.1% | |

LKR Million unless stated otherwise

# Palm Oil – Performance Highlights

## Business Highlights

The Palm Oil segment recorded a 26.1% YoY improvement in revenue in 2QFY26, driven by both volume growth and favorable Net Sales Averages for CPO and KPO.




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | 0.5% | 9.3% | -1.2% | -22.8% | 12.2% | 12.6% | 27.2% | 34.0% | 26.1% | 8.4% |
| EBIT Margin (%) | 50.9%* | | 45.4% | | 37.8% | | 55.6% | | 57.8% | |
| PAT / PAT Margin (%) | 654 | 34.4% | 478 | 32.6% | 265 | 16.0% | 852 | 38.5% | 967 | 40.3% |
| Sales Volume [CPO & KPO] (MT) | 4,147 | | 3,305 | | 3,430 | | 4,295 | | 4,613 | |

LKR Million unless stated otherwise

* Excluding Impairment on Investment in subsidiary of LKR 139m

# Dairy – Performance Highlights

## Business Highlights

The dairy business recorded a 2.9% YoY improvement in revenue improvement in 2QFY26, driven by increase in milk sales volumes during the quarter.




| Investor Metrics | 2QFY25 | | 3QFY25 | | 4QFY25 | | 1QFY26 | | 2QFY26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth % (YoY) \| (QoQ) | -16.4% | -10.8% | -25.1% | 2.9% | -26.8% | -10.7% | -14.6% | 4.1% | 2.9% | 7.5% |
| EBIT Margin (%) | 0.3%* | | 12.8% | | -16.8% | | -5.3% | | -13.4%* | |
| PAT / PAT Margin (%) | -11* | -3.8%* | -23 | -7.6% | -67 | -25.1% | -26 | -9.2% | -52* | -17.4%* |
| Sales Volume ('000) | 1,268 | | 1,310 | | 1,181 | | 1,230 | | 1,310 | |
| Average Milk Price | 229 | | 228 | | 226 | | 226 | | 229 | |

LKR Million unless stated otherwise

*2QFY25 - Adjusted for the fair value loss in Biological Assets of LKR 253m

* 2QFY26 - Adjusted for the fair value loss in Biological Assets of LKR 16m

# Q&A

# Appendix

# Sunshine Pharmaceuticals – Market Dynamics

## During 2Q IQVIA, the market experienced a growth of 7.3% (2025 MAT%)




Source – IQVIA, Management Information

SHP – Sunshine Pharmaceuticals, Market share and market growth data are based on calendar year periods and are reported with a three-month lag

*SHP's 1QFY26 & 2QFY26 growth is primarily due the internal realignment of the business model, Adjusting for this one-off impact, the RD segment grew 9.1% YoY during the 1HFY26

# Sunshine Medical Devices – Market Dynamics




Source – Management Information

# Brand Value Market Share (%) – Tea




Source: Peppercube RMS

# Brand Value Market Share (%) – Confectionary




Source: Peppercube RMS

# Price Index – Tea and Confectionary

## Tea Price Index




March 2022 considered as the base (i.e., 100)

Source – Management Information

## Confectionery Price Index




Source – World Bank Commodity Price Data, Management Information

# Agribusiness – Price Movement

## Settlement Price (RM)




Source - Malaysian contract price

## WDL's Avg Milk Price (LKR)




Source – Management Information

# Forward Looking Statements

This presentation contains forward-looking statements that are based on management's current expectations and assumptions. Forward-looking statements include predictions of future results or activities and may contain the words "expects," "believes," "should," "will," "anticipates," "projects," "estimates," "implies," "can," or words or phrases of similar meaning. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Our predictions could be affected by a variety of factors, including: competitive dynamics and the markets for our products, including new product introductions, advertising activities, pricing actions and promotional activities of our competitors; economic conditions, including changes in inflation rates, interest rates, tax rates, or the availability of capital; product development and innovation; consumer acceptance of new products and product improvements; consumer reaction to pricing actions and changes in promotion levels; acquisitions or dispositions of businesses or assets; changes in capital structure; changes in laws and regulations, including labeling and advertising regulations; impairments in the carrying value of intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets; changes in accounting standards and the impact of significant accounting estimates; product quality and safety issues, including recalls and product liability; changes in consumer demand for our products; effectiveness of advertising, marketing and promotional programs; changes in consumer behavior, trends and preferences, including weight loss trends; consumer perception of health-related issues; consolidation in the retail environment; changes in purchasing and inventory levels of significant customers; fluctuations in the cost and availability of supply chain resources, including raw materials, packaging and energy; disruptions or inefficiencies in the supply chain; benefit plan expenses due to changes in plan asset values and discount rates used to determine plan liabilities; failure or breach of our information technology systems; foreign economic conditions, including currency rate fluctuations; and political unrest in foreign markets and economic uncertainty due to terrorism or war.

**The company undertakes no obligation to publicly revise any forward-looking statements to reflect any future events or circumstances.**

# Thank you!

For more information, Please visit our Investor Relations page

https://www.sunshineholdings.lk/investor-relations/